Amarin (AMRN) Drops Most in 7 Months as FDA Makes No Determination on Vascepa
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Amarin (AMRN) Price Target Slashed 30% at MKM Partners, NCE Now "Unlikely"
October 11, 2012 10:44 AM EDTMKM Partners' Jon LeCroy, M.D. cut ihs price target on Amarin Corporation (NASDAQ: AMRN) from $21.50 to $15 on NCE and deal uncertainty, although he is maintaining a Buy rating.
After the third delay to the NCE decision, "we are now... More
Amarin (AMRN) Says Vascepa Will Not Be in FDA's Sept. Orange Book
October 10, 2012 9:18 AM EDTAmarin (Nasdaq: AMRN) filed the following 8-K with the U.S. SEC:
The U.S. Food and Drug Administration (FDA) typically publishes a determination on the exclusivity of recently approved products in a cumulative supplement to its Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book, mid-month in the month following the drugs approval. Vascepa (icosapent ethyl) capsules was approved by the FDA in July 2012.
As previously disclosed, in each of mid-August and mid-September, the FDA communicated to Amarin Corporation plc (Amarin) that it had not yet... More
